Department of Pediatric Nephrology, School of Medicine, Bezmialem Vakif University, İstanbul, Turkey.
Mol Cell Biochem. 2011 Jun;352(1-2):247-53. doi: 10.1007/s11010-011-0760-2. Epub 2011 Apr 11.
Hypertension and related oxidative stress are involved in the pathogenesis of any renal diseases. Angiotensin-converting enzyme inhibitors have multi-directional renoprotective effects. In this study, we aimed to investigate whether lisinopril treatment has any biochemical alterations on renal tissue in L-NAME (Nε-nitro-L-arginine methyl ester) induced hypertension model. Twenty-eight Sprague-Dawley rats were included in this study and divided into four equal groups (n = 7): control group, L-NAME treated group (75 mg/kg/day), L-NAME plus lisinopril treated group and only lisinopril treated group (10 mg/kg/day). L-NAME and lisinopril were continued for 6 weeks. Systolic blood pressures were measured by using tail cuff method. In biochemical analysis, malondialdehyde (MDA, an index of lipid peroxidation) levels, the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in renal tissues were used as markers of oxidative stress-induced renal impairment. Microalbumin and N-acetyl-β-D-glucosaminidase (NAG) in urine were determined as markers of renal tubular damage related to hypertension. Chronic L-NAME administration resulted in a significant depletion of serum nitric oxide (NO). When compared with control group, serum creatinine, microalbumin, urine NAG, renal tissue MDA level, and CAT activities were significantly high, while renal tissue SOD and GSH-Px activities low in L-NAME group. In the L-NAME plus lisinopril treated group, serum creatinine, microalbumin and urine NAG, renal MDA level and CAT activity decreased, whereas SOD, GSH-Px activities in renal tissue and serum NO levels were increased. Thus, lisinopril treatment reversed these effects. There were not any significant difference between L-NAME plus lisinopril treated group and control group concerning serum creatinine, renal tissue MDA level and SOD, GSH-Px, CAT activities. These results suggest that lisinopril could diminish biochemical alterations in L: -NAME induced hypertensive renal damage that occurs by oxidative stress.
高血压和相关的氧化应激参与了任何肾脏疾病的发病机制。血管紧张素转换酶抑制剂具有多向的肾保护作用。在这项研究中,我们旨在研究血管紧张素转换酶抑制剂赖诺普利治疗是否对 L-NAME(Nε-硝基-L-精氨酸甲酯)诱导的高血压模型的肾脏组织有任何生化改变。将 28 只 Sprague-Dawley 大鼠纳入本研究,并分为四组(每组 7 只):对照组、L-NAME 处理组(75mg/kg/天)、L-NAME 加赖诺普利处理组和仅赖诺普利处理组(10mg/kg/天)。L-NAME 和赖诺普利治疗持续 6 周。使用尾套法测量收缩压。在生化分析中,丙二醛(MDA,脂质过氧化的指标)水平、超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和谷胱甘肽过氧化物酶(GSH-Px)在肾脏组织中的活性被用作氧化应激引起的肾损伤的标志物。尿液中的微量白蛋白和 N-乙酰-β-D-氨基葡萄糖苷酶(NAG)被确定为与高血压相关的肾小管损伤的标志物。慢性 L-NAME 给药导致血清一氧化氮(NO)显著耗竭。与对照组相比,L-NAME 组血清肌酐、微量白蛋白、尿 NAG、肾组织 MDA 水平和 CAT 活性显著升高,而 SOD 和 GSH-Px 活性降低。在 L-NAME 加赖诺普利治疗组中,血清肌酐、微量白蛋白和尿 NAG、肾组织 MDA 水平和 CAT 活性降低,而 SOD、GSH-Px 活性和血清 NO 水平升高。因此,赖诺普利治疗逆转了这些效应。L-NAME 加赖诺普利治疗组与对照组在血清肌酐、肾组织 MDA 水平和 SOD、GSH-Px、CAT 活性方面无显著差异。这些结果表明,赖诺普利可以减轻 L-NAME 诱导的高血压肾损伤中由氧化应激引起的生化改变。